Virgin Galactic Completes New Spaceship Manufacturing Facility in Arizona

This experiment serves as a stepping stone to support astronauts with insulin-dependent diabetes and demonstrates a capability necessary for maintenance therapy and hyperglycemic states in insulindependent people with diabetes. This human-tended experiment includes two commercially available insulin pens, which will each be secured in a custom 3D-printed container during flight. During the flight, Tuva will retain the insulin pens in his flight suit, dial an insulin dose, and dispense insulin from each pen into a collection container to study the accuracy of dose dispensation in microgravity. Commercial spaceflight and the research flown on these missions are opening space to people with diabetes and those who previously have not been eligible to fly to space.

This experiment serves as a stepping stone to support astronauts with insulin-dependent diabetes and demonstrates a capability necessary for maintenance therapy and hyperglycemic states in insulindependent people with diabetes. This human-tended experiment includes two commercially available insulin pens, which will each be secured in a custom 3D-printed container during flight. During the flight, Tuva will retain the insulin pens in his flight suit, dial an insulin dose, and dispense insulin from each pen into a collection container to study the accuracy of dose dispensation in microgravity. Commercial spaceflight and the research flown on these missions are opening space to people with diabetes and those who previously have not been eligible to fly to space.
This experiment serves as a stepping stone to support astronauts with insulin-dependent diabetes and demonstrates a capability necessary for maintenance therapy and hyperglycemic states in insulindependent people with diabetes. This human-tended experiment includes two commercially available insulin pens, which will each be secured in a custom 3D-printed container during flight. During the flight, Tuva will retain the insulin pens in his flight suit, dial an insulin dose, and dispense insulin from each pen into a collection container to study the accuracy of dose dispensation in microgravity. Commercial spaceflight and the research flown on these missions are opening space to people with diabetes and those who previously have not been eligible to fly to space.

About Virgin GalacticVirgin Galactic is an aerospace and space travel company, pioneering human spaceflight for private individuals and researchers with its advanced air and space vehicles. Scale and profitability are driven by next generation vehicles capable of bringing humans to space at an unprecedented frequency with an industry-leading cost structure. You can find more information at https://www.virgingalactic.com/.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the development of our Delta Class spaceships and proposed timeline for testing and commercial service using such spaceships, the timing of the delivery of parts and assembly of the Delta Class spaceships, the scaling of our team to develop the Delta Class spaceships, the use of digital twin technology to enable integration between us and suppliers and the estimated number of monthly flights of the Delta Class spaceships are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,”“would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to, any delay in future commercial flights of our spaceflight fleet, our ability to successfully develop and test our Delta fleet and the time and costs associated with doing so, the safety of our spaceflight systems, our expected capital requirements and the availability of additional financing, and the other, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.virgingalactic.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.